MGD014

BIOLOGICAL3 trials

Sponsors

MacroGenics, University of North Carolina, Chapel Hill

Conditions

HIV (Human Immunodeficiency Virus)HIV-1-infectionHuman Immunodeficiency Virus I InfectionHuman Immunodeficiency Virus Type 1Immunodeficiency Virus Type 1, Human

Phase 1

MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy

CompletedNCT03570918

MacroGenicsHIV-1-infection

Start: 2018-09-25End: 2021-09-28Updated: 2022-09-02

A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy

CompletedNCT05261191

MacroGenicsHuman Immunodeficiency Virus I Infection, Human Immunodeficiency Virus Type 1, Immunodeficiency Virus Type 1, Human

Start: 2022-09-26End: 2024-05-29Updated: 2025-03-28

The DART DELIVER-02 Study

SuspendedNCT07217379

University of North Carolina, Chapel HillHIV (Human Immunodeficiency Virus)

Start: 2025-10-02End: 2027-02-01Target: 24Updated: 2026-08-18